Current Immunotherapeutic Approaches in Pancreatic Cancer

被引：69

作者：

Koido, Shigeo ^{[1
,2
,3
]}

Homma, Sadamu ^{[3
]}

Takahara, Akitaka ^{[1
]}

Namiki, Yoshihisa ^{[2
]}

Tsukinaga, Shintaro ^{[1
]}

Mitobe, Jimi ^{[1
]}

Odahara, Shunichi ^{[1
]}

Yukawa, Toyokazu ^{[1
]}

Matsudaira, Hiroshi ^{[1
]}

Nagatsuma, Keisuke ^{[1
]}

Uchiyama, Kan ^{[1
]}

Satoh, Kenichi ^{[1
]}

Ito, Masaki ^{[3
]}

Komita, Hideo ^{[1
]}

Arakawa, Hiroshi ^{[1
]}

Ohkusa, Toshifumi ^{[1
,2
]}

Gong, Jianlin ^{[4
]}

Tajiri, Hisao ^{[1
]}

机构：

[1] Jikei Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo 1058461, Japan

[2] Jikei Univ, Sch Med, Inst Clin Med & Res, Tokyo 1058461, Japan

[3] Jikei Univ, Sch Med, Dept Oncol, Inst DNA Med, Tokyo 1058461, Japan

[4] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA

来源：

CLINICAL & DEVELOPMENTAL IMMUNOLOGY | 2011年

关键词：

GROWTH-FACTOR RECEPTOR; COLONY-STIMULATING FACTOR; CYTOTOXIC T-LYMPHOCYTES; PHASE-III TRIAL; PERSONALIZED PEPTIDE VACCINATION; UNIVERSAL TUMOR-ANTIGEN; CELL-BASED VACCINATION; HUMAN DENDRITIC CELLS; PLUS GEMCITABINE; CARCINOMA CELLS;

D O I：

10.1155/2011/267539

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Pancreatic cancer is a highly aggressive and notoriously difficult to treat. As the vast majority of patients are diagnosed at advanced stage of the disease, only a small population is curative by surgical resection. Although gemcitabine-based chemotherapy is typically offered as standard of care, most patients do not survive longer than 6 months. Thus, new therapeutic approaches are needed. Pancreatic cancer cells that develop gemcitabine resistance would still be suitable targets for immunotherapy. Therefore, one promising treatment approach may be immunotherapy that is designed to target pancreatic-cancer-associated antigens. In this paper, we detail recent work in immunotherapy and the advances in concept of combination therapy of immunotherapy and chemotherapy. We offer our perspective on how to increase the clinical efficacy of immunotherapies for pancreatic cancer.

引用

页数：15

共 50 条

[1] Current and future immunotherapeutic approaches in pancreatic cancer treatment
Farhangnia, Pooya
Khorramdelazad, Hossein
Nickho, Hamid
Delbandi, Ali-Akbar
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
[2] Current immunotherapeutic strategies in pancreatic cancer
Plate, Janet M. D.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 16 (04) : 919 - +
[3] Immunotherapeutic Approaches in Pancreatic Adenocarcinoma: Current Status and Future Perspectives
Yee, Nelson S.
CURRENT MOLECULAR PHARMACOLOGY, 2016, 9 (03) : 231 - 241
[4] Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers
Hochnadel, Inga
Kossatz-Boehlert, Uta
Jedicke, Nils
Lenzen, Henrike
Manns, Michael P.
Yevsa, Tetyana
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (12) : 2931 - 2952
[5] Current problems in the development of specific immunotherapeutic approaches to cancer
Dalgleish, AG
JOURNAL OF CLINICAL PATHOLOGY, 2001, 54 (09) : 675 - 676
[6] Current Approaches in Development of Immunotherapeutic Vaccines for Breast Cancer
Allahverdiyev, Adil
Tari, Gamze
Bagirova, Melahat
Abamor, Emrah Sefik
JOURNAL OF BREAST CANCER, 2018, 21 (04) : 343 - 353
[7] BIOLOGICAL RESPONSE MODIFIER - IMMUNOTHERAPEUTIC APPROACHES IN PANCREATIC-CANCER
SCHMIEGEL, W
HEPATO-GASTROENTEROLOGY, 1989, 36 (06) : 456 - 458
[8] Current Approaches to Pancreatic Cancer Screening
Chhoda, Ankit
Lu, Lingeng
Clerkin, Barbara M.
Risch, Harvey
Farrell, James J.
AMERICAN JOURNAL OF PATHOLOGY, 2019, 189 (01): : 22 - 35
[9] Immunotherapeutic and Epigenetic Approaches Targeting Cancer-Testis Antigens in the Treatment of Pancreatic Cancer
Boni, A.
Thayer, S. P.
Ferrone, C.
Bausch, D.
Neyhard, N.
Cogdill, A.
Fernandez-del-Castillo, C. F.
Warshaw, A. L.
Wargo, J. A.
PANCREAS, 2009, 38 (08) : 985 - 985
[10] Immunotherapeutic Approaches in Cancer Treatment
Zhao, Lihong
Zhong, Lili
Xu, Songbai
Li, Bingjin
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (02) : 204 - 205

← 1 2 3 4 5 →